
    
      The primary objectives of the study are a) to allow patients from Bayer-sponsored trials to
      continue regorafenib treatment after their respective study has been completed, and b) to
      further assess the safety of regorafenib. Secondary objective is the documentation of drug
      tolerability.
    
  